Mapping dopamine function in primates using pharmacologic magnetic resonance imaging

Journal of Neuroscience

Volumn 24, Issue 43, 2004, Pages 9553-9560

  Jenkins, Bruce G ^a   Sanchez Pernaute, Rosario ^b   Brownell, Anna Liisa ^a   Chen, Yin Ching Iris ^a   Isacson, Ole ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b MCLEAN HOSPITAL   (United States)

Author keywords

Amphetamine; Dopamine; Macaque; MRI; Parkinson's disease; PET

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; AMPHETAMINE; DOPAMINE; DOPAMINE RECEPTOR; DOPAMINE TRANSPORTER;

ANIMAL EXPERIMENT; ARTICLE; BEHAVIOR; BLOOD VOLUME; BRAIN CIRCULATION; BRAIN REGION; CAUDATE NUCLEUS; CEREBELLUM; CINGULATE GYRUS; CONTROLLED STUDY; DENTATE NUCLEUS; MEASUREMENT; MOTOR CORTEX; MOTOR PERFORMANCE; NERVE CELL NETWORK; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEUS ACCUMBENS; OCCIPITAL LOBE; PARIETAL LOBE; PARKINSON DISEASE; PARKINSONISM; POSITRON EMISSION TOMOGRAPHY; PREMOTOR CORTEX; PRIMATE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROVOCATION TEST; PUTAMEN; SUBSTANTIA NIGRA; THALAMUS; THALAMUS PARAFASCICULAR NUCLEUS; VENTRAL TEGMENTUM;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; AMPHETAMINE; ANIMALS; BRAIN; BRAIN MAPPING; CEREBROVASCULAR CIRCULATION; COCAINE; DOPAMINE; DOPAMINE AGENTS; MACACA FASCICULARIS; MAGNETIC RESONANCE IMAGING; MOTOR ACTIVITY; PARKINSONIAN DISORDERS; POSITRON-EMISSION TOMOGRAPHY; RADIOLIGAND ASSAY;

EID: 7444221707     PISSN: 02706474     EISSN: None     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.1558-04.2004     Document Type: Article

References (47)

1. Alexander GM, Schwartzman RJ, Brainard L, Gordon SW, Grothusen JR (1992) Changes in brain catecholamines and dopamine uptake sites at different stages of MPTP parkinsonism in monkeys. Brain Res 588:261-269.
2. Bankiewicz KS, Sanchez-Pernaute R, Oiwa Y, Kohutnicka M, Cummins A, Eberling J (1999) Preclinical models of Parkinson's disease. Curr Protoc Neurosci [Suppl 9]:9.4.1-9.4.32.
3. Belliveau JW, Kennedy DN, McKinstry RC, Buchbinder BR, Weisskoff RM, Cohen MS, Vevea JM, Brady TJ, Rosen BR (1991) Functional mapping of the human visual cortex by magnetic resonance imaging. Science 254:716-719.
4. Bjorklund LM, Sanchez-Pernaute R, Chung S, Andersson T, Chen IY, McNaught KS, Brownell AL, Jenkins BG, Wahlestedt C, Kim KS, Isacson O (2002) Embryonic stem cells develop into functional dopaminergic neurons after transplantation in a Parkinson rat model. Proc Natl Acad Sci USA 99:2344-2349.
5. Breiter H, Gollub R, Weisskoff R, Kennedy D, Makris N, Berke J, Goodman J, Kantor R, Gastfriend D, Riorden J, Mathew RT, Rosen BR, Hyman SE (1997) Acute effects of cocaine on human brain activity and emotion. Neuron 19:591-611.
6. Brooks DJ (1999) Functional imaging of Parkinson's disease: is it possible to detect brain areas for specific symptoms? J Neural Transm Suppl 56:139-153.
7. Brownell AL, Elmaleh D, Meltzer P, Shoup TM, Brownell GL, Fischman AJ, Madras BK (1996) Cocaine congeners as PET imaging probes for dopamine terminals. J Nucl Med 37:1186-1192.
8. Brownell AL, Livni E, Galpern W, Isacson O (1998a) In vivo PET imaging in rat of dopamine terminals reveals functional neural transplants. Ann Neurol 43:387-390.
9. Brownell AL, Jenkins BG, Elmaleh DR, Deacon TW, Spealman RD, Isacson O (1998b) Combined PET/MRS brain studies show dynamic and long-term physiological changes in a primate model of Parkinson disease. Nat Med 4:1308-1312.
10. Chen Q, Andersen AH, Zhang Z, Ovadia A, Gash DM, Avison MJ (1996) Mapping drug-induced changes in cerebral R2* by multiple gradient recalled echo functional MRI. Magn Reson Imaging 14:469-476.
11. Chen Q, Andersen AH, Zhang Z, Ovadia A, Cass WA, Gash DM, Avison MJ (1999) Functional MRI of basal ganglia responsiveness to levodopa in parkinsonian rhesus monkeys. Exp Neurol 158:63-75.
12. Chen YC, Mandeville JB, Nguyen TV, Talele A, Cavagna F, Jenkins BG (2001) Improved mapping of pharmacologically induced neuronal activation using the IRON technique with superparamagnetic blood pool agents. J Magn Reson Imaging 14:517-524.
13. Chen YI, Galpern WR, Brownell AL, Matthews RT, Bogdanov M, Isacson O, Beal MF, Rosen BR, Jenkins BG (1997) Detection of dopaminergic neurotransmitter activity using pharmacologic MRI: correlation with PET, microdialysis, and behavioral data. Magn Reson Med 38:389-398.
14. Chen YI, Brownell AL, Galpern W, Isacson O, Bogdanov M, Beal MF, Livni E, Rosen BR, Jenkins BG (1999) Detection of dopaminergic cell loss and neural transplantation using pharmacological MRI, PET and behavioral assessment. NeuroReport 10:2881-2886.
15. Chiueh CC, Burns RS, Markey SP, Jacobowitz DM, Kopin IJ (1985) Primate model of parkinsonism: selective lesion of nigrostriatal neurons by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine produces an extrapyramidal syndrome in rhesus monkeys. Life Sci 36:213-218.
16. Choi WS, Machida CA, Ronnekleiv OK (1995) Distribution of dopamine D1, D2, and D5 receptor mRNAs in the monkey brain: ribonuclease protection assay analysis. Brain Res Mol Brain Res 31:86-94.
17. Devous Sr MD, Trivedi MH, Rush AJ (2001) Regional cerebral blood flow response to oral amphetamine challenge in healthy volunteers. J Nucl Med 42:535-542.
18. Drevets WC, Gautier C, Price JC, Kupfer DJ, Kinahan PE, Grace AA, Price JL, Mathis CA (2001) Amphetamine-induced dopamine release in human ventral striatum correlates with euphoria. Biol Psychiatry 49:81-96.
19. Dubowitz DJ, Bernheim KA, Chen DY, Bradley Jr WG, Andersen RA (2001) Enhancing fMRI contrast in awake-behaving primates using intravascular magnetite dextran nanopartieles. NeuroReport 12:2335-2340.
20. Frost JJ, Rosier AJ, Reich SG, Smith JS, Ehlers MD, Snyder SH, Ravert HT, Dannals RF (1993) Positron emission tomographic imaging of the dopamine transporter with 11C-WIN 35,428 reveals marked declines in mild Parkinson's disease. Ann Neurol 34:423-431.
21. Gash DM, Zhang A, Umberger G, Mahood K, Smith M, Smith C, Gerhardt GA (1999) An automated movement assessment panel for upper limb motor functions in rhesus monkeys and humans. J Neurosci Methods 89:111-117.
22. German DC, Manaye KF, Sonsalla PK, Brooks BA (1992) Midbrain dopaminergic cell loss in Parkinson's disease and MPTP-induced parkinsonism: sparing of calbindin-D28k-containing cells. Ann NY Acad Sci 648:42-62.
23. Hantraye P, Brownell A-L, Elmaleh D, Spearman RD, Wullner U, Brownell GL, Isacson O (1992) Dopamine fiber detection by [11C]-CFT and PET in a primate model of parkinsonism. NeuroReport 3:265-268.
24. Hemsworth BA, Neal MJ (1968) The effect of central stimulant drugs on acetylcholine release from rat cerebral cortex. Br J Pharmacol 34:543-550.
25. Honey GD, Suckling J, Zelaya F, Long C, Routledge C, Jackson S, Ng V, Fletcher PC, Williams SC, Brown J, Bullmore ET (2003) Dopaminergic drug effects on physiological connectivity in a human cortico-striatothalamic system. Brain 126:1767-1781.
26. Imbert C, Bezard E, Guitraud S, Boraud T, Gross CE (2000) Comparison of eight clinical rating scales used for the assessment of MPTP-induced parkinsonism in the Macaque monkey. J Neurosci Methods 96:71-76.
27. Innis RB, Malison RT, al-Tikriti M, Hoffer PB, Sybirska EH, Seibyl JP, Zoghbi SS, Baldwin RM, Laruelle M, Smith EO, et al. (1992) Amphetamine- stimulated dopamine release competes in vivo for [123I]IBZM binding to the D2 receptor in nonhuman primates. Synapse 10:177-184.
28. Jenkins BG, Chen IY, Mandeville JB (2002) Pharmacologic magnetic resonance imaging (phMRI). In: Biomedical imaging in experimental neuroscience (van Bruggen N, Roberts T, eds), pp 155-209. Boca Raton, FL: CRC.
29. Lindauer U, Villringer A, Dirnagl U (1993) Characterization of CBF response to somatosensory stimulation: model and influence of anesthetics. Am J Physiol 264:H1223-H1228.
30. Mandeville JB, Marota JJ, Kosofsky BE, Keltner JR, Weissleder R, Rosen BR, Weisskoff RM (1998) Dynamic functional imaging of relative cerebral blood volume during rat forepaw stimulation. Magn Reson Med 39:615-624.
31. Mandeville JB, Jenkins BG, Kosofsky BE, Moskowitz MA, Rosen BR, Marota JJ (2001) Regional sensitivity and coupling of BOLD and CBV changes during stimulation of rat brain. Magn Reson Med 45:443-447.
32. Marota JJ, Mandeville JB, Weisskoff RM, Moskowitz MA, Rosen BR, Kosofsky BE (2000) Cocaine activation discriminates dopaminergic projections by temporal response: an fMRI study in rat. NeuroImage 11:13-23.
33. Marsden CD, Obeso JA (1994) The functions of the basal ganglia and the paradox of stereotaxic surgery in Parkinson's disease. Brain 117:877-897.
34. Martinez D, Slifstein M, Broft A, Mawlawi O, Hwang DR, Huang Y, Cooper T, Kegeles L, Zarahn E, Abi-Dargham A, Haber SN, Laruelle M (2003) Imaging human mesolimbic dopamine transmission with positron emission tomography. II. Amphetamine-induced dopamine release in the functional subdivisions of the striatum. J Cereb Blood Flow Metab 23:285-300.
35. Matsumoto N, Minamimoto T, Graybiel AM, Kimura M (2001) Neurons in the thalamic CM-Pf complex supply striatal neurons with information about behaviorally significant sensory events. J Neurophysiol 85:960-976.
36. Meador-Woodruff JH, Mansour A, Grandy DK, Damask SP, Civelli O, Watson Jr SJ (1992) Distribution of D5 dopamine receptor mRNA in rat brain. Neurosci Lett 145:209-212.
37. Nguyen TV, Brownell AL, Iris Chen YC, Livni E, Coyle JT, Rosen BR, Cavagna F, Jenkins BG (2000) Detection of the effects of dopamine receptor supersensitivity using pharmacological MRI and correlations with PET. Synapse 36:57-65.
38. Nurmi E, Ruottinen H, Kaasinen VJB, Haaparanta M, Solin O, Rinne JO (2000) Progression in Parkinson's disease: a positron emission tomography study with a dopamine transporter ligand [18F]CFT. Ann Neurol 47:804-808.
39. Piccini P, Pavese N, Brooks DJ (2003) Endogenous dopamine release after pharmacological challenges in Parkinson's disease. Ann Neurol 53:647-653.
40. Price JC, Drevets WC, Ruszkiewicz J, Greer PJ, Villemagne VL, Xu L, Mazumdar S, Cantwell MN, Mathis CA (2002) Sequential H(2)(15)O PET studies in baboons: before and after amphetamine. J Nucl Med 43:1090-1100.
41. Schneider JS, Yuwiler A, Markham CH (1987) Selective loss of subpopulations of ventral mesencephalic dopaminergic neurons in the monkey following exposure to MPTP. Brain Res 411:144-150.
42. Stein EA (2001) fMRI: a new tool for the in vivo localization of drug actions in the brain. J Anal Toxicol 25:419-424.
43. Vanduffel W, Fize D, Mandeville JB, Nelissen K, Van Hecke P, Rosen BR, Tootell RB, Orban GA (2001) Visual motion processing investigated using contrast agent-enhanced fMRI in awake behaving monkeys. Neuron 32:565-577.
44. Villringer A, Rosen BR, Belliveau JW, Acerman JL, Lauffer RB, Buxton RB, Chao YS, Wedeen VJ, Brady TJ (1988) Dynamic imaging with lanthanidechelates in normal brain: contrast due to magnetic susceptibility effects. Magn Reson Med 6:164-174.
45. Wechsler LR, Savaki HE, Sokoloff L (1979) Effects of d- and 1-amphetamine on local cerebral glucose utilization in the conscious rat. J Neurochem 32:15-22.
46. Zaharchuk G, Mandeville JB, Bogdanov Jr AA, Weissleder R, Rosen BR, Marota JJ (1999) Cerebrovascular dynamics of autoregulation and hypoperfusion. An MRI study of CBF and changes in total and microvascular cerebral blood volume during hemorrhagic hypotension. Stroke 30:2197-2205.
47. Zhang Z, Andersen A, Grondin R, Barber T, Avison R, Gerhardt G, Gash D (2001) Pharmacological MRI mapping of age-associated changes in basal ganglia circuitry of awake rhesus monkeys. NeuroImage 14:1159-1167.